Serum betatrophin level of newly diagnosed and chronic diabetic patients and its relationship with metabolic parameters
Betatrophin levels in diabetes
DOI:
https://doi.org/10.22122/cdj.v10i4.668Keywords:
Betatrophin, Diabetes Mellitus Type 2, Enzyme-Linked Immunosorbent AssayAbstract
BACKGROUND: Angiopoietin-like protein 8 (ANGPTL8) that was originally called betatrophin is a novel growth factor which is mainly secreted by the liver and associated with diabetes. Hence, it can be considered as a clinical parameter for diagnosis or treatment of diabetes. However, there are more unknown features about its relationship with diabetes that need to be clarified. The aim of this study was to understand the role of progress of diabetes on betatrophin levels. Therefore, serum betatrophin level of newly diagnosed patients and patients with chronic diabetes and its relationship with metabolic parameters were investigated.
METHODS: In a cross-sectional study, previous diabetic patients were compared with new diabetic patients in terms of betatrophin and other parameters, and matching on age, gender, and body mass index (BMI) was performed. New cases were recognized by endocrinologist and chronic patients were selected in diabetes center of Tohid Hospital, Sanandaj, Iran, in 2015-2016. Background information including height, weight, waist circumference, abdomen circumference, and hip circumference were collected. Fasting blood sugar (FBS) was measured by glucometer and separated blood sera were used for insulin and betatrophin measurement by enzyme-linked immunosorbent assay (ELISA) method.
RESULTS: The mean values of the betatrophin in the new and chronic diabetic individuals were 10.30 ± 6.31 and 10.71 ± 6.31 ng/ml, respectively, and no significant differences were seen between two groups. There was no significant relationship between betatrophin with metabolic parameters; however, a positive correlation with FBS in the newly diagnosed and a negative correlation with FBS in the chronic patients were observed.
CONCLUSION: Betatrophin is closely associated with glucose metabolism. It seems that chronic diabetes does not alter betatrophin levels.
References
Lam DW, LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes. 2012; 19(2): 93-6.
World Population Review. Diabetes Rates by Country 2022 [Online]. [cited 2022]; Available from: URL: https://worldpopulationreview.com/country-rankings/diabetes-rates-by-country
Cox AR, Barrandon O, Cai EP, Rios JS, Chavez J, Bonnyman CW, et al. Resolving discrepant findings on ANGPTL8 in beta-cell proliferation: A collaborative approach to resolving the betatrophin controversy. PLoS One. 2016; 11(7): e0159276.
Abu-Farha M, Al Madhoun A, Abubaker J. The rise and the fall of betatrophin/ANGPTL8 as an inducer of beta-cell proliferation. J Diabetes Res. 2016; 2016: 4860595.
Gomez-Ambrosi J, Pascual-Corrales E, Catalan V, Rodriguez A, Ramirez B, Romero S, et al. altered concentrations in dyslipidemia evidence a role for ANGPTL8/betatrophin in lipid metabolism in humans. J Clin Endocrinol Metab. 2016; 101(10): 3803-11.
Yamada H, Saito T, Aoki A, Asano T, Yoshida M, Ikoma A, et al. Circulating betatrophin is elevated in patients with type 1 and type 2 diabetes. Endocr J. 2015; 62(5): 417-21.
Li S, Liu D, Li L, Li Y, Li Q, An Z, et al. Circulating betatrophin in patients with type 2 diabetes: A meta-analysis. J Diabetes Res. 2016; 2016: 6194750.
Maurer L, Brachs S, Decker AM, Brachs M, Leupelt V, Jumpertz von SR, et al. Weight loss partially restores glucose-driven betatrophin response in humans. J Clin Endocrinol Metab. 2016; 101(11): 4014-20.
Al-Rawashdeh A, Kasabri V, Bulatova N, Akour A, Zayed A, Momani M, et al. The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan. Diabetes Metab Syndr. 2017; 11(1): 59-67.
Lee SH, Rhee M, Kwon HS, Park YM, Yoon KH. Serum betatrophin concentrations and the risk of incident diabetes: A nested case-control study from Chungju metabolic disease cohort. Diabetes Metab J. 2018; 42(1): 53-62.
Li E, Nakata M, Shinozaki A, Yang Y, Zhang B, Yada T. Betatrophin expression is promoted in obese hyperinsulinemic type 2 but not type 1 diabetic mice. Endocr J. 2016; 63(7): 611-9.
Tuhan H, Abaci A, Anik A, Catli G, Kume T, Calan OG, et al. Circulating betatrophin concentration is negatively correlated with insulin resistance in obese children and adolescents. Diabetes Res Clin Pract. 2016; 114: 37-42.
Abu-Farha M, Abubaker J, Noronha F, Al-Khairi I, Cherian P, Alarouj M, et al. Lack of associations between betatrophin/ANGPTL8 level and C-peptide in type 2 diabetic subjects. Cardiovasc Diabetol. 2015; 14: 112.
Roth CL, Elfers C, Lass N, Reinehr T. Betatrophin: No relation to glucose metabolism or weight status in obese children before and after lifestyle intervention. Pediatr Diabetes. 2017; 18(6): 485-91.
Abu-Farha M, Sriraman D, Cherian P, AlKhairi I, Elkum N, Behbehani K, et al. Circulating ANGPTL8/betatrophin is increased in obesity and reduced after exercise training. PLoS One. 2016; 11(1): e0147367.
Barja-Fernandez S, Folgueira C, Seoane LM, Casanueva FF, Dieguez C, Castelao C, et al. Circulating betatrophin levels are increased in anorexia and decreased in morbidly obese women. J Clin Endocrinol Metab. 2015; 100(9): E1188-E1196.
Yi M, Chen RP, Yang R, Guo XF, Zhang JC, Chen H. Betatrophin acts as a diagnostic biomarker in type 2 diabetes mellitus and is negatively associated with HDL-cholesterol. Int J Endocrinol. 2015; 2015: 479157.
Gao T, Jin K, Chen P, Jin H, Yang L, Xie X, et al. Circulating betatrophin correlates with triglycerides and postprandial glucose among different glucose tolerance statuses--A case-control study. PLoS One. 2015; 10(8): e0133640.
Hu H, Sun W, Yu S, Hong X, Qian W, Tang B, et al. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014; 37(10): 2718-22.
Ozyazgan S, Onal B, Kurtulus EM, Uzun H, Akkan G, Konukoglu D. Plasma betatrophin levels of subjects classified with normal, impaired, and diabetic glucose tolerance, and subjects with impaired fasting glucose. Horm Metab Res. 2017; 49(6): 434-9.
Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab (Lond). 2010; 7: 26.
Fenzl A, Itariu BK, Kosi L, Fritzer-Szekeres M, Kautzky-Willer A, Stulnig TM, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia. 2014; 57(6): 1204-8.
Liu D, Qu H, Wang H, Duan Y, Liu F, Feng Z, et al. Relationship between serum betatrophin levels and the first-phase of glucose-stimulated insulin secretion. Obes Res Clin Pract. 2018; 12(Suppl 2): 9-15.
Wang L, Song J, Wang C, Lin P, Liang K, Sun Y, et al. Circulating levels of betatrophin and irisin are not associated with pancreatic beta-cell function in previously diagnosed type 2 diabetes mellitus patients. J Diabetes Res. 2016; 2016: 2616539.
Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Hu FB, et al. Higher plasma betatrophin/ANGPTL8 level in Type 2 Diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep. 2015; 5: 10949.
Guo K, Lu J, Yu H, Zhao F, Pan P, Zhang L, et al. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity (Silver Spring). 2015; 23(4): 793-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Chronic Diseases Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
